CL2013000607A1 - Anticuerpo o porción del mismo enlazante al antígeno caracterizado porque se une especificamente a vegfr-3. - Google Patents

Anticuerpo o porción del mismo enlazante al antígeno caracterizado porque se une especificamente a vegfr-3.

Info

Publication number
CL2013000607A1
CL2013000607A1 CL2013000607A CL2013000607A CL2013000607A1 CL 2013000607 A1 CL2013000607 A1 CL 2013000607A1 CL 2013000607 A CL2013000607 A CL 2013000607A CL 2013000607 A CL2013000607 A CL 2013000607A CL 2013000607 A1 CL2013000607 A1 CL 2013000607A1
Authority
CL
Chile
Prior art keywords
vegfr
antibody
binding
binds specifically
antigen characterized
Prior art date
Application number
CL2013000607A
Other languages
English (en)
Spanish (es)
Inventor
Bronislaw Pytowski
Krishnadatt Persaud
Nathalie Zayek
Original Assignee
Imclone Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44584686&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2013000607(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Imclone Llc filed Critical Imclone Llc
Publication of CL2013000607A1 publication Critical patent/CL2013000607A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CL2013000607A 2010-09-07 2013-03-04 Anticuerpo o porción del mismo enlazante al antígeno caracterizado porque se une especificamente a vegfr-3. CL2013000607A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US38043210P 2010-09-07 2010-09-07

Publications (1)

Publication Number Publication Date
CL2013000607A1 true CL2013000607A1 (es) 2014-04-11

Family

ID=44584686

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2013000607A CL2013000607A1 (es) 2010-09-07 2013-03-04 Anticuerpo o porción del mismo enlazante al antígeno caracterizado porque se une especificamente a vegfr-3.

Country Status (26)

Country Link
US (2) US8481034B2 (enExample)
EP (1) EP2614081B1 (enExample)
JP (1) JP2013538813A (enExample)
KR (1) KR20130042601A (enExample)
CN (1) CN103080133A (enExample)
AR (1) AR082641A1 (enExample)
AU (1) AU2011299443B2 (enExample)
BR (1) BR112013005423A2 (enExample)
CA (1) CA2809375C (enExample)
CL (1) CL2013000607A1 (enExample)
CO (1) CO6690754A2 (enExample)
CR (1) CR20130065A (enExample)
DO (1) DOP2013000039A (enExample)
EA (1) EA023331B1 (enExample)
EC (1) ECSP13012481A (enExample)
ES (1) ES2568801T3 (enExample)
GT (1) GT201300058A (enExample)
MA (1) MA34487B1 (enExample)
MX (1) MX2013002718A (enExample)
PE (1) PE20131328A1 (enExample)
PH (1) PH12013500432A1 (enExample)
SG (1) SG188265A1 (enExample)
TW (1) TWI413527B (enExample)
UA (1) UA109148C2 (enExample)
WO (1) WO2012033696A1 (enExample)
ZA (1) ZA201300804B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014064203A1 (en) 2012-10-26 2014-05-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Lyve-1 antagonists for preventing or treating a pathological condition associated with lymphangiogenesis
KR101521981B1 (ko) * 2013-07-31 2015-05-20 가톨릭대학교 산학협력단 혈액암 줄기세포 증식 또는 생착 억제용 조성물
EP3244924B1 (en) * 2015-01-15 2021-04-07 Oncoquest Pharmaceuticals Inc. Methods of increasing delivery of anti-cancer agents to targets
CA3044682A1 (en) 2016-12-02 2018-06-07 University Of Southern California Synthetic immune receptors and methods of use thereof
CN110004167A (zh) * 2019-04-16 2019-07-12 中国医学科学院血液病医院（血液学研究所） 靶向vegfr-2和/或vegfr-3嵌合抗原受体及其应用
CN111808191A (zh) * 2020-05-11 2020-10-23 廊坊天光生物技术有限公司 一种用于检测血清中vegf含量的抗体对及其用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002248372B8 (en) * 2001-01-19 2008-03-20 Vegenics Limited FLT4(VEGFR-3) as a target for tumor imaging and anti-tumor therapy
CN101277976B (zh) 2005-10-06 2012-04-11 伊莱利利公司 抗肌抑制素抗体

Also Published As

Publication number Publication date
EA023331B1 (ru) 2016-05-31
CN103080133A (zh) 2013-05-01
ZA201300804B (en) 2014-07-30
DOP2013000039A (es) 2013-04-15
CO6690754A2 (es) 2013-06-17
AU2011299443A1 (en) 2013-02-14
PE20131328A1 (es) 2013-11-18
TWI413527B (zh) 2013-11-01
US8784818B2 (en) 2014-07-22
ECSP13012481A (es) 2015-03-31
SG188265A1 (en) 2013-04-30
EA201390117A1 (ru) 2013-06-28
TW201223543A (en) 2012-06-16
MA34487B1 (fr) 2013-08-01
US8481034B2 (en) 2013-07-09
KR20130042601A (ko) 2013-04-26
CR20130065A (es) 2013-03-21
BR112013005423A2 (pt) 2016-06-07
CA2809375A1 (en) 2012-03-15
EP2614081B1 (en) 2016-03-16
WO2012033696A1 (en) 2012-03-15
GT201300058A (es) 2014-07-16
CA2809375C (en) 2016-02-09
AR082641A1 (es) 2012-12-19
US20130280278A1 (en) 2013-10-24
US20120058126A1 (en) 2012-03-08
UA109148C2 (uk) 2015-07-27
AU2011299443B2 (en) 2014-06-05
PH12013500432A1 (en) 2017-08-23
EP2614081A1 (en) 2013-07-17
MX2013002718A (es) 2013-05-01
JP2013538813A (ja) 2013-10-17
ES2568801T3 (es) 2016-05-04

Similar Documents

Publication Publication Date Title
IL262073B (en) Antibody drug conjugates (adc) that bind to 191p4d12 proteins
EP2854843A4 (en) ANTIGEN-BINDING PROTEINS FOR BINDING PD-L1
KR102355959B9 (ko) 158p1d7 단백질에 결합하는 항체 약물 컨쥬게이트
HUE042898T2 (hu) Antitestek, amelyek kötnek CSF1R-t
SMT201400184B (it) Anticorpi monoclonali che legano b7h6 e loro usi
DK2651436T3 (da) Mycobakterie antigen sammensætning.
DK2850103T3 (da) ST2-antigenbindende proteiner
PL3702368T3 (pl) Przeciwciała o zmodyfikowanym powinowactwie do FcRn, które wspomagają klierens antygenu
IL267382A (en) Oncostatin m receptor antigen binding proteins
BR112013029893A2 (pt) molécula de ligação a cd3, anticorpo de ligação a cd3, diacorpo de ligação a cd3 e composição farmacêutica
BR112014030278A2 (pt) anticorpo, e, composição.
BR112014028222A2 (pt) conjugados vinculadores auto-estabilizantes.
BR112012030311A2 (pt) anticorpo
DK2954779T3 (da) Mus, der frembringer tungkædeantistoffer
CL2011002306A1 (es) Anticuerpo o un fragmento de union a antigeno del mismo que se une especificamente a la integrina heterodimero alfa4beta7; y composicion que lo comprende.
BRPI1012694A2 (pt) anticorpos solúveis apenas com cadeia pesada
HUE041274T2 (hu) Pirrolobenzodiazepin-anti-PSMA-antitest konjugátumok
LT2906251T (lt) Pirolobenzodiazepino-anti-cd22 antikūno konjugatai
SI2906252T1 (sl) Pirolobenzodiazepin-anti-HER2 protitelesni konjugati
EP2863946A4 (en) ANTIGEN-BINDING PROTEINS THAT BIND TO C-MET
DK3351255T3 (da) Modificerede anti-cd4-antistoffer
EP2627357A4 (en) Antibodies that bind amyloid oligomers
EP2935334A4 (en) ANTIBODIES THAT FIX TO MEMBRANE-RELATED IL1 RAPID
DK3404043T3 (da) Anti-cdh3-antistof med høj internaliseringskapacitet
LT2814842T (lt) Antikūnai, kurie suriša peptidoglikaną atpažįstantį baltymą 1